BioDuro Opens New Laboratory in Shanghai for Highly Potent Compound Synthesis
BioDuro, the global contract research, development and manufacturing (CRDMO) company, has opened a new state-of-the-art laboratory in Shanghai, China for the synthesis of high-potency APIs for the pharmaceutical industry. The laboratory is equipped with advanced technologies and processes designed to ensure safety, precision, and scalability in the production of these complex compounds.
The occupational exposure band 5 (OEB-5) rated laboratory will serve as a key hub for the company’s global clients, and incorporates isolators, closed-system reactors, and a dedicated high-efficiency particulate air-filtered heating, ventilation, and air conditioning system (HVAC) to enable the production of potent compounds at the hundred-gram scale for clinical and commercial purposes.
BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), announced the opening of a new laboratory in the Waigaoqiao district/Free-Trade Zone of Shanghai, China, for highly potent compound synthesis at the hundred-gram scale. Operating within occupational exposure band 5 (OEB-5), this specialized facility is designed to accelerate discovery and early development programs for conjugated drugs, including antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and radionuclide-drug conjugates (RDCs).
The new OEB-5 lab is equipped to ensure the safe and efficient production of high potent compounds, and incorporates isolators, closed-system reactors, and a dedicated HEPA-filtered HVAC system. Its potent handling rating means that trained technicians can operate safely within an OEL of as little as 0.1 micrograms per cubic meter.
“The addition of this OEB-5 lab strengthens BioDuro’s capabilities in the development of highly potent drugs,” said Dr. Armin Spura, CEO of BioDuro. “As demand continues to grow for complex conjugated therapeutics, we remain committed to enhancing our capabilities and capacities, providing integrated solutions across chemistry, biology, and DMPK to accelerate the delivery of innovative treatments for global patients.”
For more, please find the original story source here.